AAAAAA

   
Results: 1-8 |
Results: 8
Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma:A gynecologic oncology group study
Authors: Thigpen, T Brady, MF Homesley, HD Soper, JT Bell, J
Citation: T. Thigpen et al., Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma:A gynecologic oncology group study, J CL ONCOL, 19(2), 2001, pp. 364-367
Paclitaxel in the treatment of carcinosarcoma of the uterus: A gynecologiconcology group study
Authors: Curtin, JP Blessing, JA Soper, JT DeGeest, K
Citation: Jp. Curtin et al., Paclitaxel in the treatment of carcinosarcoma of the uterus: A gynecologiconcology group study, GYNECOL ONC, 83(2), 2001, pp. 268-270
Radiographic imaging in gynecologic oncology
Authors: Soper, JT
Citation: Jt. Soper, Radiographic imaging in gynecologic oncology, CLIN O GYNE, 44(3), 2001, pp. 485-494
Combining the staging system of the International Federation of Gynecologyand Obstetrics with the scoring system of the World Heath Organization forTrophoblastic Neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society
Authors: Kohorn, EI Goldstein, DP Hancock, BW Kim, SJ Lurain, JR Newlands, E Soper, JT Wong, LC
Citation: Ei. Kohorn et al., Combining the staging system of the International Federation of Gynecologyand Obstetrics with the scoring system of the World Heath Organization forTrophoblastic Neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society, INT J GYN C, 10(1), 2000, pp. 84-88
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A gynecologic oncology group study
Authors: Sutton, G Brunetto, VL Kilgore, L Soper, JT McGehee, R Olt, G Lentz, SS Sorosky, J Hsiu, JG
Citation: G. Sutton et al., A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A gynecologic oncology group study, GYNECOL ONC, 79(2), 2000, pp. 147-153
The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma
Authors: Cirisano, FD Robboy, SJ Dodge, RK Bentley, RC Krigman, HR Synan, IS Soper, JT Clarke-Pearson, DL
Citation: Fd. Cirisano et al., The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma, GYNECOL ONC, 77(1), 2000, pp. 55-65
Oral medroxyprogesterone acetate in the treatment of advanced or recurrentendometrial carcinoma: A dose-response study by the Gynecologic Oncology Group
Authors: Thigpen, JT Brady, MF Alvarez, RD Adelson, MD Homesley, HD Manetta, A Soper, JT Given, FT
Citation: Jt. Thigpen et al., Oral medroxyprogesterone acetate in the treatment of advanced or recurrentendometrial carcinoma: A dose-response study by the Gynecologic Oncology Group, J CL ONCOL, 17(6), 1999, pp. 1736-1744
Epidemiologic and surgicopathologic findings of papillary serous and clearcell endometrial cancers when compared to endometrioid carcinoma
Authors: Cirisano, FD Robboy, SJ Dodge, RK Bentley, RC Krigman, HR Synan, IS Soper, JT Clarke-Pearson, DL
Citation: Fd. Cirisano et al., Epidemiologic and surgicopathologic findings of papillary serous and clearcell endometrial cancers when compared to endometrioid carcinoma, GYNECOL ONC, 74(3), 1999, pp. 385-394
Risultati: 1-8 |